Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline

Author:

Shapiro Charles L.1,Van Poznak Catherine2,Lacchetti Christina3,Kirshner Jeffrey4,Eastell Richard5,Gagel Robert6,Smith Sean2,Edwards Beatrice J.7,Frank Elizabeth8,Lyman Gary H.9,Smith Matthew R.10,Mhaskar Rahul11,Henderson Tara12,Neuner Joan13

Affiliation:

1. Mount Sinai Hospital, New York, NY

2. University of Michigan, Ann Arbor, MI

3. American Society of Clinical Oncology, Alexandria, VA

4. Hematology-Oncology Associates of Central New York, Syracuse, NY

5. The University of Sheffield, Sheffield, United Kingdom

6. MD Anderson Cancer Center, Houston, TX

7. University of Texas Dell Med School and Central Texas Veterans Healthcare System, Austin, TX

8. Dana-Farber Cancer Institute, Boston, MA

9. Fred Hutchinson Cancer Research Center, Seattle, WA

10. Massachusetts General Hospital Cancer Center, Boston, MA

11. University of South Florida Health, Tampa, FL

12. University of Chicago Medicine, Chicago, IL

13. Medical College of Wisconsin, Milwaukee, WI

Abstract

PURPOSE The aim of this work is to provide evidence-based guidance on the management of osteoporosis in survivors of adult cancer. METHODS ASCO convened a multidisciplinary Expert Panel to develop guideline recommendations based on a systematic review of the literature. RESULTS The literature search of the 2018 systematic review by the US Preventive Services Task Force in the noncancer population was used as the evidentiary base upon which the Expert Panel based many of its recommendations. A total of 61 additional studies on topics and populations not covered in the US Preventive Services Task Force review were also included. Patients with cancer with metastatic disease and cancer survival outcomes related to bone-modifying agents are not included in this guideline. RECOMMENDATIONS Patients with nonmetastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks that are associated with their cancer therapy. Clinicians are advised to assess fracture risk using established tools. For those patients with substantial risk of osteoporotic fracture, the clinician should obtain a bone mineral density test. The bone health of all patients may benefit from optimizing nutrition, exercise, and lifestyle. When a pharmacologic agent is indicated, bisphosphonates or denosumab at osteoporosis-indicated dosages are the preferred interventions.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 145 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3